Source comparison
PT-141 History: Comparison of Development Stages
Melanotan II Discovery 1995–1998 Injectable tanning peptide Melanocortin-induced skin pigmentation Unexpected spontaneous arousal in male trial participants Investigational only; not FDA-approved PT-141 Early Trials 2000–2004 Intranasal delivery Erectile dysfu
This comparison does not assign a generated winner or score.
- Melanotan II Discovery
- 1995–1998
- Injectable tanning peptide
- Melanocortin-induced skin pigmentation
- Unexpected spontaneous arousal in male trial participants
- Investigational only; not FDA-approved
- PT-141 Early Trials
- 2000–2004
- Intranasal delivery
- Erectile dysfunction in men; arousal in women
- Proof of concept for central melanocortin pathway in sexual response
- Phase I/II. No serious adverse events
- Intranasal Phase IIb
- 2005–2008
- Intranasal spray
- Erectile dysfunction and HSDD
- Efficacy demonstrated but transient blood pressure elevations led to voluntary halt
- Development suspended in 2008
- Subcutaneous Reformulation
- 2010–2015
- Subcutaneous injection 1.75 mg
- HSDD in premenopausal women
- Improved safety profile; lower Cmax reduced cardiovascular concerns
- Phase III trials initiated (RECONNECT)
- FDA Approval (Vyleesi)
- 2019
- Subcutaneous autoinjector
- Acquired, generalized HSDD in premenopausal women
- Statistically significant increase in satisfying sexual events and desire scores vs placebo
- FDA-approved June 2019 for HSDD
- The PT-141 history demonstrates how peptide research evolves through iterative refinement. From accidental discovery to targeted mechanism isolation to formulation optimization. Each stage addressed a specific limitation: Melanotan II was too broad in receptor activity; intranasal PT-141 raised cardiovascular safety signals; subcutaneous bremelanotide solved both while narrowing the clinical indication to the population with the strongest efficacy signal.